In a previous study, we developed a novel HER2 targeting antibody, 1E11, which was demonstrated to have significant anti-tumor activity as a single agent and synergistic effect in combination with trastuzumab in vitro and in vivo [22]. Here, ERBB2 is linked to neoplasm.